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ABSTRACT 
Mn(II), Cu(II), Zn(II) and Pt(II) complexes of 2-((p-
tolylamino)methyl)phenolyldithiocarbamate were synthesized and characterized by elemental 
analyses and spectroscopic techniques. Spectroscopic studies indicate four coordinate 
geometry around the metal(II) ions and single crystal X-ray crystallography confirmed the 
molecular structures of Cu(II) and Pt(II) complexes as distorted square planar. In vitro 
cytotoxic effects of the complexes, indicative of potential anti-cancer properties, were 
evaluated using human cancer cell lines HeLa and MRC5-SV2, and a normal cell line, MRC5. 
The complexes exhibited significant toxicity against the cancer cell lines, with IC50 values of 
less than 50µM after 48 h of exposure. Cu(II) and Zn(II) were the most potent and were 
virtually equipotent in their cytotoxicity against each of the two cancer cells, but only Zn(II) 
exhibited higher selectivity for a cancer cell than for a normal cell. Mn(II) complex was the 
least potent, while Pt(II) was the least cancer cell-selective, exhibiting significantly higher 
toxicity against the parental (normal) MRC-5 cell than against its cancer variant, MRC5-SV2. 
These compounds could, therefore, inspire the development of inorganic drug leads to generate 
novel anti-cancer drugs to be delivered directly to the cancerous tissue or through special 
delivery systems.  
Keywords: Dithiocarbamate; Metal(II) complexes; cytotoxicity; anticancer; cancer cells; 
selectivity.       





The development of metallo-pharmaceuticals has grown rapidly since the discovery of cisplatin 
and analogues [1, 2]. However, these compounds are associated with side effects such as severe 
toxicity, intrinsic or acquired resistance and narrow activity range [3, 4]. Some of these side 
effects are due to reduction in cisplatin uptake and intracellular accumulation [5]. This 
necessitates the search for alternative metallo-based compounds other than platinum [6-14]. 
Dithiocarbamate (R2NCS2
−) ions strongly coordinate and stabilize metal ions in different 
oxidation states due to the high electron density on the sulphur atoms of the dithiocarbamato 
moieties [15]. Metal dithiocarbamates have been shown to possess promising biological 
activities [16, 17]. Recent studies have shown that metal dithiocarbamates bind DNA in 
different ways, with varying cytotoxic activities [3, 18-25]. They inhibit NF-kB, which is 
known to promote tumor cell proliferation [26-28]. In continuation of our efforts to develop 
novel metallo drug candidates [3, 29, 30], we present the synthesis, characterization and in 
vitro anticancer studies of Mn(II), Cu(II), Zn(II) and Pt(II) complexes of 2-((p-
tolylamino)methyl)phenolyldithiocarbamate. The molecular structures of the Cu(II) and Pt(II) 
complexes are presented. Assessment of the anticancer potentials of the complexes focused on 
their ability both to potently exhibit cytotoxicity and to selectively kill cancer cells, using  two 
cancer cell lines (HeLa, MRC5-SV2) and a normal cell line (MRC5) parental to the MRC5-
SV2.  
 
2. Experimental  
2.1 Materials and methods 
All solvents used in this study were analytical grade and used as obtained without further 
purification. The infrared spectra of the ligand and metal complexes were recorded on Agilent 
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Cary 630 FTIR spectrometer (4000-650 cm-1), melting points were recorded on Gallenkamp 
melting point apparatus and 1H and 13C NMR were recorded on Bruker Avance III 400 MHz, 
with the carbon and proton shifts presented in ppm in relation to the relevant deuterated solvent 
signals. The elemental analyses were recorded on Thermoscientific Flash 2000. The UV-
Visible spectra were recorded on Agilent Cary 100 UV-Visible spectrophotometer. The molar 
conductivity and mass spectrometry were recorded on Jenway 4510 conductivity meter and 
Waters Micromass LCT Premier TOF-MS, respectively. Cell culture media and reagents 
(DMEM, L-glutamine, antibiotic-antimycotic solution, trypsin solution (TrypLE), phosphate-
buffered saline) were obtained from Life Technologies (ThermoFisher Scientific, UK) and 
Fetal Bovine Serum from Sigma-Aldrich (UK). Chemicals (including doxorubicin) were 
obtained from Sigma-Aldrich and Tocris Bioscience (Biotechne), UK.  
 
2.2 Synthesis of (2-((p-tolylamino)methyl)phenol) 
The secondary amine, (2-((p-tolylamino)methyl)phenol), used for the synthesis of the 
dithiocarbamate ligand was synthesized according to literature [31]. P-toluidine (2.143 g, 0.025 
mol) was added to salicylaldehyde (2.7 mL, 0.025 mol) and refluxed at 80°C for 8 h. The 
solvent was then removed under vacuum to give a yellow oily (Schiff base) product, which 
was then reduced to secondary amine with sodium borohydride (1.5132 g, 0.04 mol) added in 
portions at room temperature and stirred for 20 h. The resulting product was extracted with 
dichloromethane and washed with water to give a solid product after removing the solvent.  
Yield, 3.8817 g, 91 %, 1H NMR (400 MHz, (CD3)2CO, δ, ppm); 8.68(s, 1H), 7.25(d, 1H), 
7.05(m, 1H), 6.93(d, 2H), 6.81(m, 2H), 6.66(d, 2H), 5.08(s, 1H), 4.35(d, 2H), 2.18(s, 3H), 13C 
NMR (400 MHz, (CD3)2CO, δ, ppm); 45.26(—CH2—NH—), 20.47(—CH3), 114.60, 116.12, 
129.47, 147.45(—NH—C6H4), 156.62, 128.70, 126.42, 120.26, 127.03, 130.24((OH)C6H4—), 
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FTIR (solid, cm-1); 3368 (b), 2903 (m), 2811 (m), 1616 (s), 1582 (s), 1486 (s), 1382 (s), 1222 
(s), TOF MS ES+: Calcd C14H15NO,  m/z: [M]
+: 213.12, Found: 214.12 
 
2.3 Synthesis of the dithiocarbamate ligand  
The potassium salt of the dithiocarbamate ligand was prepared thus: Aqueous solution of KOH 
(4 mmol, 0.2244 g) was added to THF solution of the secondary amine (4 mmol, 0.8531 g) and 
stirred for one hour at room temperature. The mixture was brought down to 0-4 °C and CS2 (4 
mmol, 0.24 mL) was added and stirred for 5 h; diethyl ether was added to form pale yellow 
precipitate, washed with diethyl ether and dried over silica. 
 
Dithiocarbamate ligand (L): Yield, 1.2446 g, 95 %, m.p 165, Anal. Cal for C15H14KNOS2: C, 
55.01; H, 4.31; N, 4.28; S, 19.58. Found: C, 54.76; H, 4.08; N, 4.36; S, 19.33, Ʌm (Ω
-1cm2mol-
1); 64.31, 1H NMR (400 MHz, CD3CN, δ, ppm): 10.13(s, 1H), 7.09(m, 1H), 7.04(q, 2H), 6.77(t, 
3H), 6.52(m, 1H), 6.40(q, 1H), 5.65(s, 2H), 2.09(s, 3H), UV-Vis (CH3CN, λmax), 287 nm 
(34843 cm-1), TOF MS ES+, m/z [2M-K]+: 615.06, FTIR (ν/cm−1); 1581 (νC–N), 932 (νC–S), 
3361 (νO–H). 
 
2.4 Synthesis of the metal(II) complexes C1-C4 
The metal(II) complexes (C1-C4) were prepared thus: To aqueous solution of the potassium 
salt of 2-((p-tolylamino)methyl)phenolyldithiocarbamate (0.62 mmol, 0.2031 g), aqueous 
solutions of the corresponding metals: MnCl2·4H2O (0.31 mmol, 0.0614 g), CuCl2·2H2O (0.31 
mmol, 0.0528 g), ZnCl2 (0.31 mmol, 0.0409 g), and  K2PtCl4 (0.31 mmol, 0.1287 g) were added 
and stirred for 4-12 h. The products were filtered, washed with water and dried over vacuum 
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to obtain the metal (II) complexes. Crystals suitable for single crystal X-ray crystallography 
were obtained by slow evaporation of dichloromethane solution of Cu(II)  complex and slow 
diffusion of hexane into chloroform solution of Pt(II) . 
[Mn(L)2], (C1): Yield; 0.1915 g, 98 %, brown solid, Anal. Cal for [C30H28MnN2O2S4]: C, 
57.04; H, 4.47; N, 4.43; S, 20.30. Found: C, 56.92; H, 4.09; N, 4.64; S, 19.87, m.p; 139 °C, Λm 
(Ω-1cm2mol-1): 5.46, UV-Vis (CH3CN, λmax); 270 nm (37037 cm
-1), FTIR (ν/cm−1); 1592 (νC–
N), 956 (νC–S), 3267 (νO–H).  
 
[Cu(L)2], (C2): Yield; 0.1948 g, 98 %, brown solid, m.p; 172 °C, Λm (Ω
-1cm2mol-1): 4.16, 
Anal. Cal for [C30H28CuN2O2S4]: C, 56.27; H, 4.41; N, 4.37; S, 20.03. Found: C, 56.16; H, 
4.77; N, 4.89; S, 20.32, UV-Vis (CH3CN, λmax); 281nm (35587 cm
-1), 442 nm (22624 cm-1), 
TOF MS ES+: Calcd C30H28CuN2O2S4, m/z: [M]
+: 640.36, Found: 639.03, FTIR (ν/cm−1); 
1596 (νC–N), 951 (νC–S), 3296 (νO–H). 
 
[Zn(L)2], (C3): Yield; 0.1716, 85 %, white solid, m.p; 175 °C, Anal. Cal for 
[C30H28ZnN2O2S4]: C, 56.11; H, 4.39; N, 4.36; S, 19.97. Found: C, 56.34; H, 4.17; N, 4.05; S, 
20.22, Λm (Ω
-1cm2mol-1): 2.66, UV-Vis (CH3CN, λmax); 281 nm (35587 cm
-1), 1H NMR (400 
MHz, (CD3)2SO, δ, ppm); 9.44(s, 1H), 7.30(d, 1H), 7.06(m, 5H), 6.79(m, 1H), 6.71(d, 1H), 
5.34(s, 2H), 2.23(s, 3H), 13C NMR (400 MHz, (CD3)2SO, δ, ppm); 208.06 (C—S), 20.55 (CH3) 
56.82 (CH2), 114.97, 126.49, 128.59, 154.73 (—C6H4OCH3), 118.71, 121.41, 128.31, 129.19, 
136.87, 142.70 (—C6H4OH), FTIR (ν/cm
−1); 1596 (νC–N), 951 (νC–S), 3327 (νO–H). TOF MS 
ES+: Calcd C30H28ZnN2O2S4, m/z: [M]




[Pt(L)2], (C4): Yield; 0.2052 g, 86 %, yellow solid, Anal. Cal for [C30H28PtN2O2S4]: C, 46.68; 
H, 3.66; N, 3.63; S, 16.62. Found: C, 46.43; H, 3.39; N, 3.07; S, 16.16, m.p 221°C, Λm (Ω
-
1cm2mol-1): 4.65, UV-Vis (CH3CN, λmax); 259 nm (38610 cm
-1), 360 nm, (27777 cm-1), 1H 
NMR (400 MHz, (CD3)2SO, δ, ppm); 9.66(d, 1H), 7.12(m, 6H), 6.73(m, 2H), 5.09(d, 2H), 
2.24(d, 3H), 13C NMR (400 MHz, (CD3)2SO, δ, ppm); 213.25 (C—S), 21.15 (CH3) 51.67 
(CH2), 115.62, 127.15, 130.25, 155.89 (—C6H4OCH3), 119.38, 120.15, 129.79, 136.84, 
138.90, 155.88 (—C6H4OH), FTIR (ν/cm
−1); 1597 (νC–N), 948 (νC–S), 3400 (νO–H), TOF MS 
ES+: Calcd C30H28PtN2O2S4,  m/z: [M]
+: 771.90, Found: 772.11 
 
2.5 Single crystal X-ray crystallography  
The crystallographic data were obtained on a Bruker SMART APEX2 area detector 
diffractometer using MoKa radiation (0.934 Å). The structure was solved with the ShelXS-
2013 [32] structure solution program using the Intrinsic Phasing solution method and by using 
Olex2 [33] as the graphical interface. The model was refined with version 2016/6 of ShelXL 
[34] using Least Squares minimization. 
 
2.6 In vitro cytotoxicity studies  
Three cell lines grown as adherent monolayer cultures were used for the cytotoxicity 
experiments: Two cancer cell lines (the human cervical adenocarcinoma cell line HeLa and the 
human foetal lung cancer cell line MRC5-SV2) and one normal cell line (the human foetal lung 
fibroblast cell line MRC5, which is the parental cell line from which MRC5-SV2 was derived). 
This approach allows the assessment of the differential sensitivities of cancer and normal cell 
lines to potential anti-cancer compounds in order to assess the selectivity, or otherwise, of such 
test compounds for cancer cells. Experiments were conducted largely as previously reported 
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[4, 35]. The cells were grown in 75cm2 tissue culture flasks using Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% Foetal Calf Serum, 2mM L-glutamine and 1% 
antibiotic-antimycotic solution (containing penicillin, streptomycin and amphotericin B). They 
were incubated at 37oC in a humidified atmosphere of 5% CO2. All solutions to which the 
cultures were exposed were pre-warmed to 37oC. Upon attaining 80-90% confluency in the 
flask, the cultures were rinsed with phosphate-buffered saline (PBS), trypsinised, harvested 
into a suspension using the growth medium, counted with a haemocytometer, and seeded into 
micro-clear, flat-bottom 96-well plates at a density of 7.5 x 104 cells per ml (100µL/well, 
equating to 7500 cells per well). After a period of 24 h, cultures were exposed to a range of 
concentrations prepared in growth medium (compound stocks were prepared in DMSO but 
final DMSO concentration that cells were exposed to was not more than 0.1%v/v) as indicated 
in the results section and added to the cultures, each in triplicate, and plates were incubated for 
up to 48 h, after which viability was assessed using the MTT (3-(4,5-Dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide) assay. This was done by adding to each well 10µL of 
MTT solution (5mg/mL, prepared in sterile PBS) and incubating the plates for 3 h, after which 
the content of each well was aspirated and 100µl of DMSO was added to dissolve the insoluble 
formazan. The absorbance of each well was then read at a wavelength of 570nm using the 
CLARIOstar plate reader (BMG Labtech). These values are indicative of the viability of the 
cultures following treatments with the compounds. Changes to the morphology of the cells 
caused by the treatments were monitored on an Olympus CKX41 microscope fitted with an 
Olympus DP71 U-TVIX-2 camera. Images were captured using the Olympus cellSens entry 
software. 
 
For each treatment the mean of the triplicate values was calculated. The mean of the negative 
control culture was then set to 100% and the mean viability for each concentration normalised 
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to it. Values are shown as Mean ± SEM (standard error of the mean). Statistical analyses were 
done using GraphPad (Version 8.0.1) (GraphPad Software, Inc., CA, USA). Statistically 
significant differences between the means were determined using analysis of variance 
(ANOVA) followed by a post-hoc test for multiple comparisons (Tukey test). A P-value of less 
than 0.05 was considered statistically significant. IC50 value for each compound was 
determined using GraphPad by fitting the data to the non-linear regression “log [inhibitor] 
versus response (3 parameters or 4 parameters (variable slope))”. To calculate the Selectivity 
Index (SI) for each compound, the IC50 value for its cytotoxic effect in the normal cell MRC5 
was divided by the IC50 value for its cytotoxic effect in the cancer variant MRC5-SV2.   
 
3. Results and discussion 
3.1 Syntheses 
The compounds were prepared as shown in Scheme 1. The complexes (C1-C4) were obtained 
as solid in good yield ranging from 67-98%.  The molar conductance of the complexes in 
comparison with that of the ligand in dichloromethane revealed that they were neutral as 
expected [35]. The elemental analysis and spectroscopic data agree with the proposed four 
coordinate geometry with two molecules of the dithiocarbamate ligands bonded to the metal(II) 
ions. Single crystal X-ray crystallography of Cu(II) and Pt(II) complexes revealed  





Scheme 1. General synthetic pathway for the preparation of the ligand and the complexes 
 
3.2 Spectroscopic studies 
The intense bands observed at 1581 and 932 cm-1 in the FTIR spectrum of the free ligand were 
assigned to the thioureide ν(C—N) and ν(C—S) stretching vibrations of the N—CSS moiety 
and the broad band observed at 3361 cm-1 was assigned to ν(O—H). In the metal complexes, 
the ν(C—N) stretching vibrations shifted by 14 cm-1 to higher energies, which indicates an 
increase of the carbon—nitrogen double bond character [29, 30, 37]. The ν(C—S) stretching 
vibrations observed at 932 cm-1 in the ligand shifted to 956, 951, 951, and 948 cm-1 in the 
spectra of Mn(II), Cu(II), Zn(II) and Pt(II) complexes, respectively. This confirms the 
coordination of the ligand to the metal(II) ions in a bidentate chelating mode via the two sulphur 
atoms [38-40].   
 
The electronic spectra of the ligand and corresponding metal(II) complexes in dimethyl 
sulfoxide are presented in Figure 1. The band at 287 nm (34843 cm-1) in the electronic 
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spectrum of the ligand is assigned to the intraligand n—π and π—π* transitions of the N—CSS 
moiety of the dithiocarbamate. The Mn(II) (C1) is a d5 complex with zero crystal field 
stabilization energy in which electronic transitions are both spin and Laporte forbidden, hence 
no d-d transition was observed [41]. The band observed at 270 nm (37037 cm-1) is assigned to 
ligand to metal charge transfer transitions typical of four coordinate Mn(II) complex [42]. 
 
In the electronic spectra of copper(II) complexes in square planar geometry, two absorption 
bands in the visible region due to 2B1g→
2A1g and 
2B1g→
2Eg are expected [43, 44]; however, in 
Cu(II) complex (C2), the only band at 442 nm (22624 cm-1) is assigned to 2B1g→
2A1g, while 
the second band was not observed. In the Zn(II) complex (C3), the band at 281 nm (35587 cm-
1) is assigned to ligand to metal charge transfer transitions (LMCT) [43]. The electronic 
spectrum of the Pt(II) complex (C4) showed strong and intense absorption at 259 nm (38610 
cm-1) and is assigned to intraligand (π—π*). The d-d-transition is masked by charge transfer 
transition observed at 360 nm (27777 cm-1) [45].  
 
3.3 Molecular structures of the Cu(II) and Pt(II) complexes 
The molecular structures of the Cu(II) and Pt(II) complexes are shown in Figures 2 and 4. The 
crystallographic data and structure refinements are presented in Table 1. Selected bond lengths 
and bond angles are listed in Tables 2 and 3 for Cu(II) and Pt(II), respectively. The Cu(II) 
complex C2 crystalized out as centrosymmetric mononuclear entity consisting of two 
molecules of the dithiocarbamate ligand symmetrically bonded to the Cu(II) ions (Figure 2). 
The geometry around the copper(II) ion in the complex is a four coordinate distorted square 
planar geometry ascribed to the cis S1—Cu1—S2 of (77.803(19)°) and trans S1—Cu1—S21 
of (102.197(19)°) bite angles. The average Cu—S bond length is 2.30 Å in agreement with 
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reported four coordinate copper(II) dithiocarbamate complexes [29, 46, 47]. The thioureide 
N—CSS is planar with sp2 hybridized carbon and the N—CSS bond length of 1.318(3) Å. This 
is shorter than the C—N single bond (1.465 Å) and longer than C═N double bond (1.279 Å). 
This indicates partial double bond character of the N—C due to the delocalized π-electron 
density over the thioureide (NCS2) moiety [48]. The thioureide S1—C1 and S2—C1 are 
1.730(2) Å and 1.723(2) Å, which are shorter than normal C—S single bond length (1.81 Å) 
but longer than C═S bond length (1.69 Å) [29, 46, 47].   
 
The molecular structure is sustained in the unit cell by non-classical intra molecular C—H···S 
and secondary inter molecular O—H···S hydrogen bonding (Figure 3). The two aryl rings of 
the N-substituent are not coplanar with dihedral angle of 67.13° between the two planes (C2, 
C3, C4, C5, C7, C8 and C10, C11, C12, C13, C14, C15). The non-coplanar nature of these 
rings may provide some required minimum degree of steric shelter needed for effective drug 
delivery because of anticipated moderate ligand exchange kinetics.  
 
The Pt(II) complex crystalized out in an orthorhombic crystal system and space group P212121. 
The compound is a monomeric (Figure 4) four-coordinate platinum(II) center with two 
molecules of the ligand in a distorted square planar geometry duet to the S1—Pt1—S2 
(74.92(12)°)  and S3—Pt1—S4 (74.68(12)°)  bite angles. The unequal platinum-sulfur bond 
lengths: Pt1—S1 (2.303(3) Å), Pt1—S2 (2.321(3) Å), Pt1—S3 (2.329(4) Å), Pt1—S4 
(2.336(3) Å) indicate the ligands are asymmetrically bonded to the platinum(II) ion [49].  
The thioureide C—N bond lengths: N1—C8 (1.290(17) Å) and N2—C16 (1.295 Å) are shorter 
than normal carbon-nitrogen single bond (1.465 Å) and greater than carbon-nitrogen double 
bond (1.279 Å) strong carbon-nitrogen double bond character as a result of π-electron density 
delocalization within the NCS2 moiety. Also, the thioureide C—S bond lengths are unequal in 
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the range 1.721-1.755(14) Å and lie between C—S (1.815 Å) and C=S (1.671 Å) bond lengths. 
This indicates the delocalization of π-electrons in the S—C—S group [50]. The unit cell 
packing of [Pt(L)2] consists of four molecules in a unit cell with non-classical intramolecular 
C—H···S and O—H···S hydrogen bond interactions.   
  
 
3.4 Assessment of the potential anticancer properties of the complexes  
The cytotoxicity of complexes C1-C4 against cancer cell lines was assessed to determine their 
potential anti-cancer properties. The three cell lines used, HeLa (cervical cancer cell line), 
MRC5-SV2 (lung cancer cell line) and MRC5 cells (normal (healthy) lung fibroblast cells), 
were exposed to the standard drug, cisplatin, and to each of C1-C4, for 24 and/or 48 hours. 
Cisplatin (6.25-100µM) significantly reduced the viabilities of HeLa, MRC5-SV2 and MRC-
5 cells in a concentration-dependent manner, with IC50 values, respectively, of 11.1 ± 3.3µM, 
8.6 ± 0.3µM and 15.0 ± 0.4µM for 48 h of exposure (Table 4).  
 
The extent of viability reductions caused by cisplatin (or each of the complexes) was consistent 
with the degree of morphological damage inflicted on the cells (Figure 7). The concentration-
dependence of the toxic effects (for cisplatin and the complexes) was also demonstrated 
morphologically by the progressive worsening of the toxicity phenotype with increasing 
concentrations. Compared to the negative control cultures that remained adhered to the 
substratum, appeared confluent and demonstrated network processes consistent with the typical 
morphology of the different cell types used, the toxicity phenotype was characterized by a 
rounding up of the cells, shrinkage of the cells and, in some cases, significant loss of cells 




The MRC5-SV2 cell was more sensitive to cisplatin than the HeLa cell, whereas the MRC5 
cell was less sensitive to cisplatin than the HeLa cell. On the other hand, both the MRC5-SV2 
and the MRC5 cells were more sensitive to the complexes than the HeLa cell. The Selectivity 
Index (SI) values for cisplatin and the complexes were also determined. SI is the ratio of the 
IC50 value for the toxicity of a compound against a normal cell line (MRC5 in this case) and 
the IC50 value for its toxicity against a cancer cell line or a cancerous variant of the normal cell 
line (MRC5-SV2 in this case) [51]. A SI greater than 1 suggests the compound is more selective 
for the cancer cell (desirable), while a SI less than 1 suggests the compound is more toxic to a 
normal cell than a cancer cell (undesirable). Cisplatin had a Selectivity Index (SI) of 1.7 (48 h) 
(Table 4), meaning it was nearly twice as toxic to the cancer cell line MRC5-SV2 as it was to 
its parental (normal) cell line MRC5.  
 
The complexes elicited varying degrees of toxicity. Mn(II) complex (C1) was the least toxic 
(Figure 6D-F), with IC50 values (48 h) of 45.6 ± 3.9µM, 37.7 ± 3.0µM, and 29.9 ± 3.9µM, for 
the HeLa, MRC5-SV2 and MRC5 cells, respectively, translating to a SI of 0.8 (Table 4), which 
implies it was more toxic to the normal cell line MRC5 than to the  cancer variant MRC5-SV2. 
Both Cu(II) (C2) and Zn(II) (C3) complexes exhibited concentration-dependent toxic effects, 
both on viability (Figure 6A-C for Cu(II) and Figure 6D-F for Zn(II)) and on morphology 
(Figure 7). There was no difference between the toxicities of Cu(II) at 24 h and 48 h. 
 
While Cu(II) and Zn(II) complexes elicited similar toxicity potencies against the two cancer 
cell lines (HeLa and MRC5-SV2), Cu(II) complex was more toxic to the MRC5 cell line than 
Zn(II) complex. The IC50 values for the effects (48 h) of Cu(II) on HeLa, MRC5-SV2 and 
MRC5 cells are 30.1 ± 3.5µM, 17.9 ± 2.1µM, and 14.0 ± 3.5µM, respectively, and for Zn(II) 
the values are 28.1 ± 1.8µM, 19.8 ± 0.2µM, and 22.3 ± 1.9µM (Table 4). Cu(II) produced a SI 
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of 0.8 while the SI for Zn(II) was 1.1. This means Cu(II) complex exhibited greater toxicity 
against the normal cell line MRC5 than against its cancer variant MRC5-SV2, whereas Zn(II) 
complex exhibited marginally greater toxicity against the cancer cell line MRC5-SV2 than 
against its parental (normal) cell line MRC5.  
 
While Pt(II) complex (C4) also reduced the viability of each of the three cell lines in a 
concentration-dependent manner (Figure 6D-F) and caused morphological damage, it was less 
toxic to both cancer cell lines (HeLa and MRC5-SV2) than either Cu(II) or Zn(II) complex, 
but more toxic to the normal cell line MRC5 than either of them (Table 4). This resulted in 
Pt(II) being the complex with the least SI (0.3), which establishes it as significantly more toxic 
to the normal cell line (MRC5) than its cancer variant (MRC5-SV2). The ranking orders of 
potencies for the four complexes are Zn(II)>Cu(II)>Pt(II)>Mn(II) for the HeLa cell line, 
Cu(II)>Zn(II)>Pt(II)>Mn(II) for the MRC5-SV2 cell line and Pt(II)>Cu(II)>Zn(II)>Mn(II) for 
the MRC5 cell line. Overall, based on the findings, Zn(II) complex appears the most promising 
compound that might induce significant death of cancer cells while being selective, at least, 
mildly, for those cancer cells over normal cells.  
 
However, further studies of the complexes could determine their SIs in a wider selection of 
cancer cells and their parental (normal) cells in order to ascertain whether the complexes could 
exhibit differential toxicities and selectivity in different cancer types. Furthermore, as there is 
now the possibility of using special delivery systems to target anti-cancer drugs specifically to 
cancer cells and thus spare normal cells [52], all the four complexes could still be investigated 
for their potential to generate leads for the development of novel, inorganic anti-cancer drugs. 
They could lend themselves to further modifications to enhance cancer cell toxicity potency 




Mn(II), Cu(II), Zn(II) and Pt(II) dithiocarbamate complexes were prepared and characterized 
by elemental analyses, spectroscopic techniques and the Cu(II) and Pt(II) by single crystal X-
ray crystallography. Spectroscopic studies confirmed that two molecules of the 
dithiocarbamate ligand coordinate the metal(II) ions in a bidentate chelating mode to form four 
coordinate geometry. Single crystal X-ray structures of the Cu(II) (C2) and Pt(II) (C4) 
complexes revealed a distorted four coordinate square planar geometry. All the four complexes 
showed in vitro cytotoxic activity against the HeLa and MRC5-SV2 cancer cell lines, with IC50 
values of less than 50µM. Cu(II) and Zn(II) complexes demonstrated the highest cytotoxicity 
potencies (IC50 values ranging between 20 and 30µM), while Zn(II)  was the only ligand that 
exhibited (marginally) selective toxicity against cancer cells. These complexes, therefore, have 
potential to generate leads for the development of novel, inorganic anti-cancer compounds. 
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Table 1. Crystal data and structure refinements for Cu(II) and Pt(II) 
Compound  [Cu(L)2] [Pt(L)2] 
Formula  C30H28CuN2O2S4  C30H28N2O2PtS4  
Dcalc./ g cm
-3  1.277  1.333  
μ/mm-1  0.934  3.888  
Formula Weight  640.32  771.87  
Size/mm3  0.33×0.26×0.14  0.37×0.23×0.18  
T/K  100(2)  100(2)  
Crystal System  triclinic  orthorhombic  
Space Group  P-1  P212121  
a/Å  7.1091(6)  28.219(6)  
b/Å  9.6797(7)  17.750(4)  
c/Å  13.6943(10)  7.6800(16)  
α/°  69.535(4)  90  
β/°  89.651(4)  90  
γ/°  71.724(4)  90  
V/Å3  832.65(11)  3846.8(14)  
Z  1  4  
Z’ 0.5  1  
Wavelength/Å  0.71073  0.71073  
Radiation type MoKa  MoKa  
Θmin/°  1.598  2.749  
Θmax/°  28.347  25.995  
Measured Refl.  15481  13956  
Independent Refl.  4126  7216  
Reflections Used  3267  6642  
Rint  0.0313  0.0853  
Parameters  183  309  
Restraints  0  229  
Largest Peak   0.394  3.376  
Deepest Hole  -0.316  -1.758  
GooF  0.996  1.035  
wR2 (all data)  0.0915  0.1514  
wR2  0.0862  0.1487  
R1 (all data)  0.0510  0.0655  









Table 2. Some selected bond lengths and bond angles for [Cu(L)2] 
Atoms Angle/° Atoms Length/Å 
S11—Cu1—S1 180.0 Cu1—S11 2.3076(5) 
S21—Cu1—S1 102.196(19) Cu1—S1 2.3076(5) 
S2—Cu1—S11 102.197(19) Cu1—S2 2.2948(5) 
S21—Cu1—S11  77.803(19) Cu1—S21 2.2948(5) 
S2—Cu1—S1  77.803(19) S1—C1 1.730(2) 
S2—Cu1—S21 180.0 S2—C1 1.723(2) 
C1—S1—Cu1 83.78(7) O1—C15 1.369(2) 
C1—S2—Cu1 84.33(7) N1—C1 1.318(3) 
S2—C1—S1 113.65(12) C2—C8 1.381(3) 
N1—C1—S1 123.86(16) C3—C4 1.386(3) 
N1—C1—S2  122.46(16) C4—C5 1.386(4) 
Symmetry operation 1-x,1-y,-z; 21-x,-y,-z; 3+x,-1+y,+z 
 
 
Table 3. Some selected bond lengths and bond angles for [Pt(L)2] 
Atoms Angle/° Atoms Length/Å 
S1— Pt1— S2 74.92(12) Pt1—S1 2.303(3) 
S1—Pt1—S3 105.05(12) Pt1—S2 2.321(3) 
S1—Pt1—S4 178.45(12) Pt1—S3 2.329(4) 
S2—Pt—S3 179.86(15) Pt1—S4 2.336(3) 
S2—Pt1—S4 105.35(12) S1—C8 1.755(14) 
S3—Pt1—S4 74.68(12) S2—C8 1.721(14) 
C8—S1—Pt1 88.1(5) S3—C16 1.730(14) 
C8—S2—Pt1 88.3(5) S4—C16 1.726(14) 
S2—C8—S1 108.0(7) C4—C5 1.390(1) 
N1—C8—S1 124.1(11) C4—C7 1.538(15) 















Table 4: IC50 values (mean ± SEM) (in µM) and selectivity indices for the toxicities of the 
anti-cancer drug, cisplatin, and Complexes C1-C4 against HeLa, MRC5-SV2 and MRC5 
cells. Selectivity Index (SI) is the ratio of the IC50 value for the toxicity of a compound against 
a normal cell line (MRC5 in this case) and the IC50 value for its toxicity against a cancerous 
variant of the normal cell line (MRC5-SV2 in this case). A SI greater than 1 suggests the 
compound is more selective for the cancer cell (desirable), while a SI less than 1 suggests the 




IC50 (µM)   
HeLa MRC5-SV2 MRC5 
Selectivity  
Index (SI) 
Cisplatin (standard) 11.1 ± 3.3   8.6 ± 0.3 15.0 ± 0.4 1.7 
[Mn(L)2], C1   45.6 ± 3.9 37.7 ± 3.0 29.9 ± 3.9 0.8 
[Cu(L)2], C2  30.1 ± 3.5 17.9 ± 2.1 14.0 ± 3.5 0.8 
[Zn(L)2], C3 28.1 ± 1.8 19.8 ± 0.2 22.3 ± 1.9 1.1 
 [Pt(L)2], C4   39.7 ± 10.3 26.9 ± 0.3   7.4 ± 0.9 0.3 
Order of potencies 























Figure 1. Overlay spectra of the ligand (L) and the complexes: (C1) Mn(II), (C2) Cu(II), 
(C3) Zn(II) and (C4) Pt(II) 
 
Figure 2. The molecular structure of Cu(II) complex with atom numbering thermal 





























Figure 3. Molecular packing of Cu(II) viewed down crystallographic b-axis of the unit cell 
with the supramolecular layer sustained by intra molecular C—H···S and  O—H···S 
interactions.  
 
Figure 4. The molecular structure of [Pt(L)2] with atom numbering thermal ellipsoids 50% 






Figure 5. The unit cell packing of [Pt(L)2] with hydrogen atoms omitted for clarity and 




















Figure 6: Effects of up to 48 h exposure to Complexes C1 ([Mn[L]2]), C2 ([Cu(L)2]), C3 
([Zn(L)2]) and C4 ([Pt(L)2])  on the viability of HeLa, MRC5-SV2 and MRC5 cells. (A). 
Effects of C2 (24 and 48 h) on HeLa cells. (B) Effects of C2 (24 and 48 h) on MRC5-SV2 
cells. (C). Effects of C2 (24 and 48 h) on MRC5 cells. (D) Effects of C1, C3 and C4 (48 h) on 
HeLa cells. (E). Effects of C1, C3 and C4 (48 h) on MRC5-SV2 cells. (F) Effects of C1, C3 
and C4 (48 h) on MRC-5 cells. Each bar represents the mean ± SEM of triplicate viability 
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values obtained as cellular (cytotoxic) response to treatment with the indicated concentration 
of the indicated compound. *P<0.05, **P<0.001 and ***P<0.0001 compared with negative 











Figure 7: Representative photomicrographs showing the effects of the anti-cancer drug, 
cisplatin, and Complexes C2 ([Cu(L)2]) and C3 ([Zn(L)2]) on the morphology of HeLa and 
MRC5-SV2 cells following 48 h exposure to each compound. Bright-field images were 
acquired with a 10x objective on an Olympus CKX41 microscope fitted with an Olympus DP71 
U-TVIX-2 camera. Dead or dying cells are indicated by their rounded and/or shrunken 

























Figure S7. FTIR spectrum of ligand (L) 
 
 




Figure S9. FTIR spectrum of C2 
 
 




Figure S11. FTIR spectrum of C4 
 
 











Figure S14. Mass spectrum of C2 
 
 





Figure S16. 1H and 13C NMR spectra of C4 
 
 
 
 
 
